Země: Austrálie
Jazyk: angličtina
Zdroj: Department of Health (Therapeutic Goods Administration)
voriconazole, Quantity: 40 mg
Arrotex Pharmaceuticals Pty Ltd
Suspension, powder for
Excipient Ingredients: sodium citrate dihydrate; citric acid monohydrate; xanthan gum; sucrose; titanium dioxide; sodium benzoate; colloidal anhydrous silica; Flavour
Oral
70mL (after reconstitution)
(S4) Prescription Only Medicine
VORICONAZOLE PFS GenPar is indicated for treatment of the following fungal infections:,Invasive aspergillosis.,Serious Candida infections (including C. krusei), including oesophageal and systemic Candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,Serious fungal infections caused by Scedosporium spp and Fusarium spp.,Other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,Prophylaxis in patients who are at high risk of developing invasive fungal infections. The indication is based on studies including patients undergoing haematopoietic stem cell transplantation.
Visual Identification: White to off-white powder providing a white to off-white orange flavored suspension when reconstituted.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Child resistant closure
Registered
2019-03-22